Back to top

Analyst Blog

In a bid to expand its home infusion business, BioScrip Inc. (BIOS - Analyst Report) inked a definitive agreement to take over Ohio-based CarePoint Partners Holdings and its subsidiaries for cash payment of $223 million.

This lucrative acquisition is expected to leverage BioScrip’s top-line. It should also boost the company’s return on capital (ROC) going forward. Moreover, post integration (12-15 months), the acquisition is expected to improve the long-term growth prospects of the company.

For its latest acquisition, BioScrip envisages tax benefit of $45 million, yielding a net purchase price of $178 million. The acquisition is expected to close in the third quarter of 2013, subject to standard closing conditions.

CarePoint Partners is a provider of home and alternate-site infusion therapy for complex, acute and chronic illness across the U.S. It has 28 service sites in nine states, concentrated in the Gulf Coast and East Coast regions. As a leading national provider of infusion therapy to about 20,500 patients on an annual basis, CarePoint Partners expects to generate annual revenues of $160 million.

Following the acquisition, BioScrip will serve over 0.1 million patients across the U.S. with its home infusion services. The company also expects to improve standards of patient care. As per management, the deal will support BioScrip in achieving its growth targets in the long term.

BioScrip continues to expand its Infusion services business via inorganic means. Expected for closure later this year, the buyout will seamlessly strengthen the company’s foothold in the U.S.

On the tepid side, BioScrip failed to trim losses in the last quarter. Although the company’s Infusion services segment and Home Health segment is doing well, weakness in the PBM services segment remains an overhang.

Further, reimbursement cuts and adverse business mix leading to margin pressure continues to drag the financial results for BioScrip. Also worth mentioning is the tough competitive landscape with larger players and deeper resources.

The stock carries a Zacks Rank #4 (Sell). With optimism over the recently announced acquisition we expect analysts to pull estimates upward providing upward directional pressure on the Zacks Rank. Also, shares gained 5.3% to close at $15.79 on Monday.

While we avoid this medical sector stock at present, other stocks such as GNC Holdings Inc. (GNC - Snapshot Report), Herbalife Ltd. (HLF - Snapshot Report) and Rite Aid Corporation (RAD - Analyst Report), carrying a Zacks Rank #2 (Buy) are expected to do well.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%